An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
The Journal of Prosthetic Dentistry was founded in 1951 to provide a means for the interchange of ideas among individuals to advance the skill and knowledge of prosthodontics.Based on a critical review process and guided by the foremost authorities in all disciplines of prosthetic and restorative dentistry, The Journal of Prosthetic Dentistry will continue to communicate the standard for prosthetic and restorative care of patients.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Against the difficult and trying backdrop of the pandemic, cancer investigators persisted, and for patients with lung cancer, that persistence paid off in spectacular ways. With several new FDA approved treatments, as well as 2 new targetable mutations in non-small cell lung cancer (NSCLC), 2020 was a banner year in the overall lung cancer space. ONCOLOGY® recently sat down with Jennifer W. Carlisle, MD, of Emory University's Winship Cancer Institute, to discuss the many advances made during the last year for patients with lung cancer along with her hopes for further significant milestones in the year to come.
ONCOLOGY® recently sat down with Hope S. Rugo, MD, FASCO professor of medicine and director of breast oncology and clinical trials at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, to discuss some of the data presented at this year's SABCS and their implications for the future treatment of patients with breast cancer.
SARCLISA is an anti-CD38 therapy proven to deliver superior PFS (median PFS, 11.53 months with SARCLISA + Pd vs 6.47 months with Pd alone, HR=0.596, 95% CI: 0.44, 0.81, P=0.0010).SARCLISA also demonstrated a signifi cant increase in ORR (60.4% with SARCLISA + Pd [95% CI: 52.2%, 68.2%] vs 35.3% with Pd alone [95% CI: 27.8%, 43.4%], P<0.0001) 1 * Indication SARCLISA (isatuximab-irfc) is indicated, in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. Important Safety Information CONTRAINDICATIONSSARCLISA is contraindicated in patients with severe hypersensitivity to isatuximab-irfc or to any of its excipients. WARNINGS AND PRECAUTIONS Infusion-Related ReactionsInfusion-related reactions (IRRs) have been observed in 39% of patients treated with SARCLISA.All IRRs started during the fi rst SARCLISA infusion and resolved on the same day in 98% of the cases.The most common symptoms of an IRR included dyspnea, cough, chills, and nausea.The most common severe signs and symptoms included hypertension and dyspnea.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Antimicrobial resistance patterns in urinary
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Chlorhexidine-related ventilator-associated events: Toward recognition?-CORRIGENDUM Centers for medicare and medicaid services hospital-acquired conditions policy for central line-associated bloodstream infection (CLABSI) and catheter-associated urinary tract infection (CAUTI) shows minimal impact on hospital reimbursement -CORRIGENDUM Blood culture utilization at an academic hospital: Addressing a gap in benchmarking -CORRIGENDUM
Nosocomial impact of prevalent ß-lactamases from the community enterobacteriaceae: what to
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
William Soares Pugliese合作论文数UFPRGS91
Gina Mayhall合作论文数87Suzanne Bradley合作论文数82Carol E Chenoweth合作论文数47
Preeti Malani合作论文数School of Public Health, University of Michigan;Division of Infectious Diseases, Department of Internal Medicine, University of Michigan Medical School45New York合作论文数44
David Jay Weber合作论文数Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina;Department of Medicine, University of North Carolina School of Medicine44
Ebbing Lautenbach合作论文数Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania41Rodney L. Dunn合作论文数34
David P. Calfee合作论文数Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, Cornell University33
Carol E. Chenoweth合作论文数Department of Epidemiology, University of Michigan, Ann Arbor;Internal Medicine, University of Michigan, Ann Arbor,28Eli N. Perencevich合作论文数28
Curtis J. Donskey合作论文数Department of Medicine, Louis Stokes Cleveland VA Medical Center;Case Western Reserve University28M Mrvica合作论文数26
William Rutala合作论文数Division of Infectious Diseases, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill24
Andreas F. Widmer (Andreas Widmer)合作论文数Universitatsspital Basel24Rob Blixt合作论文数23Furuno Jon P合作论文数23Van Schooneveld Trevor合作论文数Nebraska Medical Center, University of Nebraska Medical Center22
Lindsay E. Nicolle合作论文数Rady Faculty of Health Sciences, University of Manitoba21Emma Mi合作论文数19
Victoria J. Fraser合作论文数Division of Infectious Diseases, John T. Milliken Department of Medicine, School of Medicine, Washington University in St. Louis;Clinical Research Training Center, Washington University in St. Louis;Barnes-Jewish Hospital;Barnes-Jewish West County Hospital19
Keith Kaye合作论文数Division of Infectious Diseases, University of Michigan Medical School;Department of Medicine, University of Michigan Medical School19
Donald A. Goldmann合作论文数Division of Infectious Diseases, Boston Children's Hospital;Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health;Department of Epidemiology, Harvard T.H. Chan School of Public Health18David Ne合作论文数17Apisarnthanarak Anucha合作论文数Div Infect Dis, Thammasat Univ Hosp17
Anthony D. Harris合作论文数School of Medicine, University of Maryland17
Linda M Mundy合作论文数Department of Community Health, Saint Louis University School of Public Health17Sickbert-Bennett Emily E合作论文数16
Trish Perl合作论文数Department of Internal Medicine, The University of Texas Southwestern Medical Center16
Susan E. Coffin合作论文数Division of Infectious Diseases, Children's Hospital of Philadelphia;Perelman School of Medicine, University of Pennsylvania16
Neil O. Fishman合作论文数Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania15
Philip M. Polgreen合作论文数Department of Internal Medicine, Carver College of Medicine, University of Iowa15
Nasia Safdar合作论文数Division of Infectious Disease, Department of Medicine, School of Medicine and Public Health, University of Wisconsin;Division of Geriatrics, Department of Medicine, School of Medicine and Public Health, University of Wisconsin;Department of Population Health, University of Wisconsin;Department of Industrial and Systems Engineering, College of Engineering, University of Wisconsin15
Deverick John Anderson合作论文数Department of Medicine, Duke University School of Medicine14
Sara Cosgrove合作论文数Division of Infectious Disease, School of Medicine, Johns Hopkins University;Department of Epidemiology, School of Public Health, Johns Hopkins University14Saiman Lisa合作论文数14
Leonard A. Mermel合作论文数Warren Alpert Medical School, Brown University;Department of Epidemiology and Infection Control, Rhode Island Hospital;Department of Medicine, Brown University14
Dan Diekema合作论文数Division of Infectious Diseases, Department of Internal Medicine, Carver College of Medicine, University of Iowa;Maine Medical Center14Gordon Rudy合作论文数13Geneva Switzerland合作论文数13Thomas R Talbot合作论文数13
Rebekah Moehring合作论文数Department of Medicine, School of Medicine, Duke University School of Medicine13
Mark E. Rupp合作论文数Department of Internal Medicine, College of Medicine, University of Nebraska Medical Center13
McGregor Jessina C合作论文数Coll Pharm, Oregon State Univ13
Michael Klompas合作论文数Department of Population Medicine, Harvard Pilgrim Health Care Institute, Harvard Medical School13
Susan S. Huang合作论文数School of Medicine, University of California, Irvine13
Didier Pittet合作论文数Faculty of Medicine, University of Geneva;World Health Organization Collaborating Centre, Geneva University Hospital13Ḿanaging Editor合作论文数12
